{"id":52782,"date":"2023-01-11T10:02:24","date_gmt":"2023-01-11T09:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/"},"modified":"2023-01-11T10:02:24","modified_gmt":"2023-01-11T09:02:24","slug":"mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/","title":{"rendered":"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies."},"content":{"rendered":"
\n

GENEVA–(BUSINESS WIRE)–#CARTCell<\/a>–MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism <\/b>and rejuvenation<\/b>, today announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx\u2019s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by Plutus Investment Group, a London-based family office, and received additional funding from business angels.\n<\/p>\n

<\/a><\/p>\n

\nMPC Therapeutics spun-off from University of Geneva (UNIGE) in 2018 to develop molecules able to modulate mitochondrial function<\/b> and trigger cellular re-programming to fight cancer and degenerative diseases<\/b>. Based on the pioneering work of Prof. Jean-Claude Martinou, the company was able to screen, optimize and patent small molecule compounds which specifically inhibit the Mitochondrial Pyruvate Carrier (MPC).\n<\/p>\n

\nImproving cell immunotherapies against cancer<\/b>\n<\/p>\n

\nThe MPC Tx\u2019s lead program aims to improve the performance and durability of CAR-T cell therapy<\/b>. Preparation of CAR-T cells in the presence of the MPC Therapeutics\u2019 compound have been shown in different preclinical cancer models to dramatically improve survival compared to standard CAR-T cells.\n<\/p>\n

\nRapha\u00ebl Martinou, CEO and co-founder of MPC Therapeutics<\/b> said: \u201cCAR-T cell therapies give hope to patients that failed to respond to earlier cancer treatments, yet too often these patients still relapse one year after CAR-T cell therapy. Reprogramming T-cells by modulating their metabolism could really transform sub-optimal treatments into highly performing life-saving ones.\u201d\n<\/p>\n

\nTowards a 2024 clinical trial and diversification in alopecia<\/b>\n<\/p>\n

\nThe seed investment funding will enable MPC Tx to advance its T-cell therapy adjuvant programme into the clinic by 2024. In addition, as modulating mitochondrial function has been shown to promote stem cell proliferation<\/b>, the team plans to position its proprietary molecules as novel treatments for alopecia<\/b>.\n<\/p>\n

\nMohammed Jamal, CEO and founder of Plutus Investment Group<\/b>, said \u201cWe are happy to have invested in MPC Therapeutics, this expands our reach into life sciences. MPC Therapeutics have world-class expertise and can become a leading biotech in the rapidly-growing cell therapies and cell rejuvenation markets.\u201d\n<\/p>\n

\nAbout MPC Therapeutics<\/b>\n<\/p>\n

\nMPC Therapeutics believe that mitochondria represent untapped therapeutic targets. Based on a deep understanding of cell metabolism and medicinal chemistry, it develops a new generation of small molecules able to modulate mitochondrial function, changing cell behaviour and reversing the course of disease.\n<\/p>\n

\nwww.mpc-therapeutics.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPR Contact<\/b>
Augustin de Bettignies, CCO
\n
+33680515180
\n
Augustin.debettignies@mpc-therapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GENEVA–(BUSINESS WIRE)–#CARTCell–MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx\u2019s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by Plutus Investment Group, a London-based family … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52782","6":"format-standard","7":"category-industry"},"yoast_head":"\nMPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies. - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies. - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GENEVA–(BUSINESS WIRE)–#CARTCell–MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx\u2019s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by Plutus Investment Group, a London-based family ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-11T09:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230111005190\/en\/1682532\/21\/Logo_MPC.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies.\",\"datePublished\":\"2023-01-11T09:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/\"},\"wordCount\":401,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005190\\\/en\\\/1682532\\\/21\\\/Logo_MPC.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/\",\"name\":\"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies. - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005190\\\/en\\\/1682532\\\/21\\\/Logo_MPC.jpg\",\"datePublished\":\"2023-01-11T09:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005190\\\/en\\\/1682532\\\/21\\\/Logo_MPC.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230111005190\\\/en\\\/1682532\\\/21\\\/Logo_MPC.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies. - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/","og_locale":"en_US","og_type":"article","og_title":"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies. - Pharma Trend","og_description":"GENEVA–(BUSINESS WIRE)–#CARTCell–MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx\u2019s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by Plutus Investment Group, a London-based family ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-11T09:02:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230111005190\/en\/1682532\/21\/Logo_MPC.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies.","datePublished":"2023-01-11T09:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/"},"wordCount":401,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230111005190\/en\/1682532\/21\/Logo_MPC.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/","url":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/","name":"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies. - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230111005190\/en\/1682532\/21\/Logo_MPC.jpg","datePublished":"2023-01-11T09:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230111005190\/en\/1682532\/21\/Logo_MPC.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230111005190\/en\/1682532\/21\/Logo_MPC.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mpc-therapeutics-announces-completion-of-its-chf-1-5m-seed-funding-round-to-improve-car-t-cancer-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies."}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52782"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52782\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}